{
    "clinical_study": {
        "@rank": "105830", 
        "acronym": "DC-TC", 
        "arm_group": {
            "arm_group_label": "DC-TC+GM-CSF", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Although liver resection, liver transplantation, a-interferon, Transarterial Chemo\n      Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous  microwave\n      coagulation therapy (PMCT), Radiofrequency ablation (RFA) provide options to treat patients\n      with HCC, the high recurrence rate of mid-late stage liver cancer still exists. The safety\n      of autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma (HCC) Patients\n      Following Resection and TACE Therapy  will be evaluated."
        }, 
        "brief_title": "Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy", 
        "condition": "Primary Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a single center,open label trial. To obtain safety information on toxicities\n      and  adverse events attributable to the subcutaneous injections of autologous dendritic\n      cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF in\n      patients with HCC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Voluntary written informed consent signed by patient or legal guardian, obtained\n             prior to study enrollment.\n\n          2. BCLC Classification A-B\n\n          3. Patients who are good surgical candidates for HCC resection\n\n          4. ECOG Performance Score, 0-1\n\n          5. Child-Pugh Rating, A\n\n          6. Expected survival greater than 6 months\n\n        Exclusion Criteria:\n\n          1. History of anaphylactic reaction to GM-CSF\n\n          2. Congestive heart failure, unstable angina or other underlying cardiac disease;\n             history of thrombosis currently requiring anticoagulation\n\n          3. Mental or psychological illness preventing cooperation with treatment, efficacy\n             evaluations, or unable to understand the informed consent process\n\n          4. Primary cancers of any kind or location, other than hepatocellular carcinoma\n\n          5. Excluding hepatitis, any active or unresolved infection including HIV, EBV, CMV, RPR,\n             TB, etc.\n\n          6. Autoimmune disease requiring therapy; immunodeficiency, or any disease process\n             requiring immunosuppressive therapy.\n\n          7. Prior clinical trial requiring patient to receive an investigational drug within two\n             weeks of enrollment.\n\n          8. Pregnant or lactating women.\n\n          9. Patients with the intention to receive transplantation\n\n         10. Significant comorbidity or other active medical condition that could be eminently\n             life threatening in the opinion of the investigator, including no active blood\n             clotting or bleeding diathesis.\n\n         11. Evidence of metastatic disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828762", 
            "org_study_id": "040420100005"
        }, 
        "intervention": {
            "arm_group_label": "DC-TC+GM-CSF", 
            "intervention_name": "DC-TC+GM-CSF", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DC", 
            "Immunotherapy", 
            "TC"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200235"
                }, 
                "name": "9585 Humin Road,Xuhui district"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy", 
        "overall_official": {
            "affiliation": "Shanghai 85 Hospital", 
            "last_name": "Chengwei Chen", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The number of adverse events along with the results of vital signs measurements, physical examinations, and clinical laboratory tests will be used to determine the safety profile of DC-TC.", 
            "measure": "Vital signs\uff0cphysical examinations and adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cellular Biomedicine Group Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Shanghai 85 Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "China Cell Technology Ltd. licensed CBMG to conduct the clinical trial as the sponsor in China", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Cellular Biomedicine Group Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}